EGFR and non-small cell lung carcinoma: Additionally, two inhibitors targeting EGFR exon 20 insertions, such as amivantamab and mobocertinib, have been recently approved for the treatment of patients with advanced NSCLC with progression after platinum-based chemotherapy79–81 (Table 2).